Selected Publications

  1. Nikhil K, Shah K* (2023) CDK5: an oncogene or an anti-oncogene: location location location. Molecular Cancer 22(1), 186. doi: 10.1186/s12943-023-01895-8.
  2. Yang W, Shah K and Yang R (2023) Editorial: Cell signaling in cancer metastasis and lineage plasticity. Front. Cell Dev. Biol. 11:1302659. doi: 10.3389/fcell.2023.1302659.
  3. Malik M, Kumar D, Lotana H, Shah K*, Kumar D*. (2023) Design, synthesis and anticancer activity of N-aryl indolylsulfoximines: Identification of potent and selective anticancer agents. Bioorganic & Medicinal Chemistry 93:117459. doi: 10.1016/j.bmc.2023.117459.

  4. Shah K*, Cook M. (2023) LIMK2: A Multifaceted Kinase with pleiotropic roles in human physiology and pathologies. Cancer Letters 565:216207. DOI: 10.1016/j.canlet.2023.216207.

  5. Yan Y, Zhou B, Qian C, Vasquez A, Kamra M, Chatterjee A, Lee YJ, Yuan X, Ellis L, Di Vizio D, Posadas EM, Kyprianou N, Knudsen BS, Shah K, Murali R, Gertych A, You S, Freeman MR, Yang W. (2022) Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis. Nat Commun. 13(1), 669.

  6. Sooreshjani MA, Kamra M, Zoubeidi A, Shah K*. (2021) Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models. J Biomed Sci. 28(1), 68. doi:10.1186/s12929-021-00765-z.

  7. Sooreshjani MA, Nikhil K, Kamra M, Nguyen D, Kumar D, Shah K*. (2021) LIMK2-NKX3.1 Engagement Promotes Castration Resistant Prostate Cancer. Cancers (Basel) 13(10), 2324;

  8. Nikhil K, Haymour HS, Kamra M, Shah K*. (2021) Phosphorylation-Dependent Regulation of SPOP by LIMK2 promotes Castration Resistant Prostate Cancer. British J Cancer 124(5), 995-1008. DOI: 10.1038/s41416-020-01197-6

  9. Nikhil K, Kamra M, Raza A, Shah K*. (2021) Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo. Cancer Lett. 498, 1-18. DOI: 10.1016/j.canlet.2020.09.010
  10. Nikhil K, Kamra M, Raza A, Haymour HS, Shah K*. (2020) Molecular Interplay between AURKA and SPOP Dictates CRPC Pathogenesis via Androgen Receptor. Cancers (Basel)  12(11), 3247. DOI: 10.3390/cancers12113247

  11. Nikhil K, Raza A, Haymour H, Flueckiger B, Chu J, Shah K* (2020) Aurora Kinase A-YBX1 Synergy Fuels Aggressive Oncogenic Phenotypes and Chemoresistance in Castration-Resistant Prostate Cancer. Cancers (Basel) 12(3), 660;
  12. Zheng X-F,  Acharya S, Choe K, Kumar Nikhil K, Adelmant G, Satapathy SR, Sharma S, Nishita Parnandi N, Viccaro K, Rana S, Natarajan A, Sicinski P, Marto J, Shah K, Chowdhury D. (2019) A mitotic CDK5-PP4 phospho-signaling cascade primes 53BP1 for DNA repair in G1. Nature Communications 10,  4252, 1-10.

  13. Shah K*, Kim H. (2019) The significant others: Global search for direct kinase substrates using chemical approaches. IUBMB Life 71(6), 721-737.

  14. Nikhil K, Chang L, Viccaro K, Jacobsen M, McGuire C, Satapathy SR, Tandiary M, Broman MM, Cresswell G, He YJ, Sandusky GE, Ratliff TL, Chowdhury D, Shah K*. (2019) Identification of LIMK2 as a Therapeutic Target in Castration Resistant Prostate Cancer. Cancer Lett. 448, 182-196. 

  15. Nikhil K, Viccaro K, Shah K*. (2019) Multifaceted Regulation of ALDH1A1 by Cdk5 in Alzheimer's Disease Pathogenesis. Mol Neurobiol 56(2), 1366-1390.
  16. Yan Y, Chang L, Tian H, Wang L, Zhang Y, Yang T, Li G, Hu W, Shah K, Chen G, Guo Y. (2018) 1-Pyrroline-5-carboxylate released by prostate Cancer cell inhibit T cell proliferation and function by targeting SHP1/cytochrome c oxidoreductase/ROS Axis. Journal for ImmunoTherapy of Cancer 6(1), 148. doi: 10.1186/s40425-018-0466-z.

  17. Chaitanya M, Reddy V, Nikhil K, Shah K*, Kumar D. (2018) Synthesis and anticancer activity studies of indolylisoxazoline analogues. Bioorganic & Medicinal Chemistry Letters  28(17), 2842-2845.

  18. Pollan SG, Huang F, Sperger JM, Lang JM, Morrissey C, Cress AE, Chu CY, Bhowmick NA, You S, Freeman MR, Spassov DS, Moasser MM, Carter WG, Satapathy SR, Shah K, Knudsen BS. (2018) Regulation of inside-out β1-integrin activation by CDCP1. Oncogene 37(21), 2817-2836. doi: 10.1038/s41388-018-0142-2.

  19. Reddy POV, Hridhay M, Nikhil K, Khan S, Jha PN, Shah K*, Kumar D (2018) Synthesis and investigations into the anticancer and antibacterial activity studies of β-carboline chalcones and their bromide salts. Bioorganic & Medicinal Chemistry Letters 28(8), 1278-1282. doi: 10.1016/j.bmcl.2018.03.033.
  20. Shah K*, Rossie S. (2018) Tale of the Good and Bad Cdk5: Remodeling of the Actin Cytoskeleton in the Brain. Mol Neurobiol 55(4), 3426-3438. doi: 10.1007/s12035-017-0525-3.

  21. Nikhil K, Shah K*. (2017) Cdk5-Mcl-1 Axis Promotes Mitochondrial Dysfunction and Neurodegeneration in Alzheimer Disease Model. J Cell Sci 130(18), 3023-3039.

  22. Rajasekhar K, Narayanaswamy N, Murugan NA, Viccaro K, Lee HG, Shah K, Govindaraju T. (2017) Aβ Plaque-Selective NIR Fluorescence Probe to Differentiate Alzheimer's Disease from Tauopathies. Biosensors and Bioelectronics. 98, 54-61. doi: 10.1016/j.bios.2017.06.030.

  23. Wang J, Nikhil K, Viccaro K, Lei C, White J, Shah K*.(2017) Phosphorylation-dependent Regulation of ALDH1A1 by Aurora Kinase A: Insights on their Synergistic Relationship in Pancreatic Cancer. BMC Biology, 15, 10. doi: 10.1186/s12915-016-0335-5.

  24. Wang J, Nikhil K, Viccaro K, Lei C, Jacobsen M, Sandusky G, Shah K*. (2017) Aurora A-Twist1 Axis Promotes Highly Aggressive Phenotypes in Pancreatic Carcinoma. J Cell Sci. 130(6), 1078-1093. doi: 10.1242/jcs.196790.

  25. Shah K*, Lahiri DK. (2017) A Tale of the Good and Bad: Remodeling of the Microtubule Network in the Brain by Cdk5. Mol Neurobiol. 54(3), 2255-2268. doi:10.1007/s12035-016-9792-7.

  26. Reddy V, Mishra S, Tantak MP, Nikhil K, Sadana R, Shah K* and Kumar D. (2017) Design, synthesis and in vitro cytotoxicity studies of novel β-carbolinium bromides. Bioorg Med Chem Lett. 27(6), 1379-1384. doi: 10.1016/j.bmcl.2017.02.010.

  27. Shi C, Viccaro K, Lee HG, Shah K*. (2016) Cdk5-FOXO3a axis: initially neuroprotective, eventually neurodegenerative in Alzheimer’s disease models. J Cell Sci. 129, 1815-1830.  doi: 10.1242/jcs.185009.

  28. Sundaree S, Shi C, Vaddula B, Tantak MP, Shah K*, Kumar D. (2016) Synthesis and Anticancer Activity Study of Indolyl hydrazide-hydrazones. Medicinal Chemistry Research 25, 91.

  29. Tantak MP, Gupta V, Nikhil K, Arun V, Singh RP, Jha PN, Shah K*, Kumar D. (2016) Sequential one-pot synthesis of bis(indolyl)glyoxylamides: Evaluation of antibacterial and anticancer activities. Bioorg Med Chem Lett. 26(13), 3167-71.

  30. Tantak MP, Wang J, Singh RP, Kumar A, Shah K*, Kumar D. (2015) 2-(3'-Indolyl)-N-arylthiazole-4-carboxamides: Synthesis and evaluation of antibacterial and anticancer activities. Bioorg Med Chem Lett. 25(19), 4225-31.

  31. Shah K*, Lahiri DK (2014) Cdk5 in the Brain, Multiple Paths of Regulation,J Cell Sci. 127(Pt 11), 2391-400.

  32. Perez FP, David Bose D, Nho K, Shah K, Lahiri DK (2014) Late-Onset Alzheimer’s Disease, Heating up and Foxed by several proteins: Pathomolecular Effects of the Aging Process.J Alzheimer Disease 40(1), 1-17.

  33. Tantak MP, Kumar A, Noel B, Shah K*, Kumar D. (2013) Synthesis and biological evaluation of 2-arylamino-5- (3'-indolyl)-1,3,4-oxadiazoles as potent cytotoxic agents.ChemMedChem. 8(9), 1468-74.

  34. Johnson EO, Chang KH, Ghosh S, Venkatesh C, Giger K, Low PS, Shah K*. (2012) LIMK2 is a Crucial Regulator and Effector of Aurora A-Mediated Malignancy.J Cell Science 125 (Pt 5), 1204-16.

  35. Chang KH, Vincent F, Shah K*. (2012) Deregulated Cdk5 Triggers Aberrant Activation of Cell Cycle Kinases and Phosphatases Inducing Neuronal Death. J Cell Sci 125(Pt 21), 5124-37.

  36. Kumar D, Kumar NM, Noel B, Shah K*. (2012) A series of 2-arylamino-5-(indolyl)-1,3,4-thiadiazoles as potent cytotoxic agents.Eur J Med Chem. 55, 432-8.

  37. Kumar D, Arun V, Maruthi Kumar, Acosta G, Noel B, Shah K*. (2012) A Facile Synthesis of Novel Bis-(indolyl)-1,3,4-oxadiazoles as Potent Cytotoxic Agents.Chem Med Chem 7(11), 1915-20.

  38. Kumar D, Kumar NM, Ghosh S, Shah K*. (2012) Novel bis(indolyl)hydrazide-hydrazones as potent anticancer agents.Bioorg Med Chem Lett. 22(1), 212-5.

  39. Johnson EO, Chang KH, de Pablo Y, Ghosh S, Mehta R, Badve S, Shah K*. (2011) PHLDA1 is a Crucial Negative Regulator and Effector of Aurora A Kinase in Breast Cancer.J Cell Science 124, 2711-2722.

  40. Sun KH, Chang KH, Clawson S, Ghosh, S, Mirzaei H, Regnier, F, Shah K*. (2011) Glutathione S-transferase P1 is a Critical Regulator of Cdk5 Kinase Activity.J Neurochem 118(5), 902-14.

  41. Chang KH, Multani PS, Sun KH, Vincent F, de Pablo Y, Ghosh S, Gupta R, Lee HP, Lee HG, Smith MA, Shah K*. (2011) Nuclear Envelope Dispersion Triggered by Deregulated Cdk5 Precedes Neuronal Death.Mol Biol Cell 22(9), 1452-62.

  42. Kumar D, Patel G, Chavers A, Chang KH, Shah K*. (2011) Synthesis of novel 1,2,4-oxadiazoles and analogues as potential anticancer agents.Eur J Med Chem 46(7), 3085-92.

  43. Kumar D, Vadulla BR, Chang KH, Shah K*. (2011) One-pot synthesis and anticancer studies of 2-arylamino-5-aryl-1,3,4-thiadiazoles.Bioorg Med Chem Lett 21(8), 2320-3.

  44. Kumar D, Kumar NK, Chang KH, Gupta R, Shah K*. (2011) Synthesis and in-vitro anticancer activity of 3,5-bis(indolyl)-1,2,4-thiadiazoles.Bioorg Med Chem Lett. 21(19):5897-900.

  45. Kumar D, Kumar NM, Chang KH, Shah K*. (2011) Synthesis of Novel Indolyl-1,2,4-triazoles as Potent and Selective Anticancer Agents.Chem Biol Drug Design 77, 182-8.

  46. Chi X, Amet T, Byrd D, Chang KH, Shah K, Hu S, Grantham A, Duan J, Nicol G, Yu Q (2011) Direct effects of HIV-1 Tat protein on excitability and survival of primary dorsal root ganglion neurons: possible contribution to HIV-1-associated pain.PLOS ONE 6(9), e24412. doi:10.1371.

  47. Chang KH, Pablo Y, Lee H, Lee H, Smith M, Shah K*. (2010) Cdk5 is a Major Regulator of p38 Cascade: Relevance to Neurotoxicity in Alzheimer’s Disease.J Neurochem 113(5), 1221-9.

  48. Kumar D, Maruthi Kumar N, Chang KH, Shah K*. (2010) Synthesis and anticancer activity of 5-(3-indolyl)-1,3,4-thiadiazoles.Eur J Med Chem. 45(10):4664-8.

  49. Kumar D, Kumar M, Sundaree S, Johnson E, Shah K*. (2010) An expeditious synthesis and anticancer activity of novel 4-(3'-indolyl)oxazoles.Eur J Med Chem 45(3), 1244-9.

  50. Sun KH, Lee HG, Smith MA, Shah, K*. (2009) Direct and Indirect Roles of Cdk5 as an Upstream Regulator in the JNK Cascade: Relevance to Neurotoxic Insults in Alzheimer’s Disease. Mol Biol Cell 20(21), 4611-9.

  51. Das M, Wiley DJ, Chen X, Shah K, Verde F. (2009) The conserved NDR kinase Orb6 controls polarized cell growth by spatial regulation of the small GTPase Cdc42.Current Biology 19, 1314-9.

  52. Kumar D, Sundaree S, Johnson EO, Shah, K*. (2009) An efficient synthesis and biological study of novel indolyl-1,3,4-oxadiazoles as potent anticancer agents.Bioorg Med Chem Lett. 19(15), 4492-4.

  53. Kumar D, Patel G, Johnson EO, Shah, K*. (2009) Synthesis and anticancer activities of novel 3,5-disubstituted-1,2,4-oxadiazoles.Bioorg Med Chem Lett 19(10), 2739-41.

  54. Sun KH, de Pablo Y, Vincent F, Johnson EO, Chavers AK, Shah K*. (2008) Novel Genetic Tools Reveal Cdk5's Major Role in Golgi Fragmentation in Alzheimer's Disease.Mol Biol Cell. 19(7), 3052-69.

  55. Sun KH, de Pablo Y, Vincent F, Shah K*. (2008) Deregulated Cdk5 Promotes Oxidative Stress and Mitochondrial Dysfunction.J Neurochem. 107, 265-278.

  56. Vincent F, Cook S, Johnson EO, Emmert D, Shah K*. (2007) Engineering Unnatural Nucleotide Specificity to Probe G protein SignalingChem Biol 14(9), 1007-18.

    (Research Highlights: Stevens K. (2007) Designer Modulators Nature Methods 4(12), 988; 

    Review: Erickson JW, Cerione RA.(2008) A new tool for G protein analysis ACS Chem Biol. 3(1):24-6.

  57. Oh H, Ozkirimli E, Shah K, Harrison ML, Geahlen RL. (2007) Generation of an analog-sensitive Syk Tyrosine Kinase for Studying Signaling Dynamics from the B Cell Antigen Receptor. J Biol Chem 282, 33760-8.

  58. Kim S, Shah K*. (2007) Dissecting Yeast HOG1 MAP Kinase Pathway Using a Chemical Genetic Approach FEBS Lett. 581(6), 1209-16.

  59. Schauble S, King CC., Darshi M, Koller A, Shah K, Taylor S.S. (2007) Identification of ChChd3 as a novel substrate of PKA using an analog-sensitive catalytic subunit.J Biol Chem. 282(20), 14952-9.

  60. Endo S, Satoh Y, Shah K, Takishima K. (2006) A single amino-acid change in ERK1/2 makes the enzyme susceptible to PP1 derivatives Biochem Biophys Res Commun. 341(1), 261-5.

  61. Juris SJ, Shah K, Shokat K, Dixon JE, Vacratsis P.O. (2006) Identification of otubain 1 as a novel substrate for the Yersinia protein kinase using chemical genetics and mass spectrometry FEBS Lett. 580(1), 179-83.

  62. Shah K*, Vincent F. (2005) Divergent roles of c-Src in controlling platelet-derived growth factor-dependent signaling in fibroblasts Mol Biol Cell. (11), 5418-32.

  63. Stauffer EA, Scarborough JD, Hirono M, Miller ED, Shah K, Mercer JA, Holt JR, Gillespie PG. (2005) Fast adaptation in vestibular hair cells requires myosin-1c activity Neuron 47(4), 541-53.

  64. Shah K*. (2005) Orthogonal Chemical Genetic Approaches for Unraveling Signaling Pathways IUBMB Life 57(6):397-405.

  65. Woodring PJ, Meisenhelder J, Johnson SA, Zhou GL, Field J, Shah K, Bladt F, Pawson T, Niki M, Pandolfi PP, Wang JYJ, Hunter T. (2004) c-Abl phosphorylates Dok-1 during filopodia formationJ Cell Biol 165(4), 493-503.

  66. Provance DW Jr, Gourley CR, Silan CM, Cameron LC, Shokat KM, Goldenring JR, Shah K, Gillespie PG, Mercer JA. (2004) Chemical-genetic inhibition of a sensitized mutant myosin Vb demonstrates a role in peripheral-pericentriolar membrane traffic Proc Natl Acad Sci U S A. 101(7), 68-73.

  67. Hindley AD, Park S, Wang L, Shah K, Wang Y, Hu X, Shokat KM, Kolch W, Sedivy JM, Yeung KC. (2004) Engineering the serine/threonine protein kinase Raf-1 to utilise an orthogonal analogue of ATP substituted at the N(6) position FEBS Lett. 556(1-3), 26-34.

  68. Ubersax JA, Woodbury EL, Quang PN, Paraz M, Blethrow J, Shah K, Shokat KM, Morgan DO (2003) Targets of cyclin-dependent kinase Cdk1Nature 425, 859-64.

  69. Eblen ST, Kumar NV, Shah K, Henderson MJ, Watts CK, Shokat KM, Weber MJ. (2003) Identification of novel ERK2 substrates through use of an engineered kinase and ATP analogsJ Biol Chem 278(17), 14926-35.

  70. Shah K, Shokat K.M. (2003) A Chemical Genetic Approach for the identification of direct substrates identification of protein kinases. Protein Kinase C Protocols (Methods in Molecular Biology, edited by A.C. Newton, Humana Press, Totowa, NJ) 233, 253-71.

  71. Shah K, Shokat KM. (2002) A Chemical Genetic Screen for Direct v-Src substrates reveals Ordered Assembly of a Retrograde Signaling PathwayChemistry & Biology 9(1), 35-47.

  72. Holt JR, Gillespie SKH, Provance Jr W, Shah K, Shokat KM, Corey DP, Mercer JA, Gillespie PG. (2002) A Chemical-Genetic Strategy Demonstrates Myosin1c Mediates Adaptation by Hair CellsCell 108(3), 371-381.

  73. Witucki LA, Huang X, Shah K, Liu L, Kyin S, Eck MJ, Shokat KM. (2002) Mutant Tyrosine Kinases with Unnatural Nucleotide Specificity Retain the Structure and Phospho-acceptor Specificity of the Wild-Type EnzymeChemistry & Biology 9(1), 25-33.

  74. Ting AY, Witte K, Shah K, Kraybill B, Shokat KM, Schultz PG. (2001) Phage Display Evolution of tyrosine kinases with altered nucleotide specificity Biopolymers; 60(3), 220-8.

  75. Wang Z, Shah K, Rana TM. (2001) Probing Tat peptide-TAR RNA interactions by psoralen photo-cross-linking Biochemistry 40(21), 6458-64.

  76. Habelhah H, Shah K, Huang L, Burlingame AL., Shokat KM, Ronai Z. (2001) Identification of a new JNK substrate using ATP pocket mutant ADK and Corresponding ATP analogueJ Biol Chem. 276(21), 18090-5.

  77. Habelhah H, Shah K, Huang L, Ostareck-Lederer A, Burlingame AL, Shokat KM, Hentze MW, Ronai Z. (2001) ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition on mRNA translationNature Cell Biology 3, 325-330.

  78. Liu Y, Witucki L, Shah K, Bishop AC, Shokat KM. (2000) Src-Abl Tyrosine Kinase Chimeras: Replacement of the Adenine Binding Pocket of c-Abl with v-Src to Swap Nucleotide and Inhibitor SpecificitiesBiochemistry 39(47), 14400-8.

  79. Ulrich S, Buzko O, Shah K, and Shokat KM. (2000) Engineering a conditionally Orthogonal Protein Kinase/Nucleotide Triphosphate PairTetrahedron 56, 9495-9502.

  80. Bishop A, Buzko O, Heyeck-Dumas S, Jung I, Kraybill B, Liu Y, Shah K, Ulrich S, Witucki L, Yang F, Zhang C, and Shokat KM. (2000) "Unnatural Ligands For Engineered Proteins: New Tools for Chemical Genetics" Annu. Rev. Biophys. Biomolec. Struct. 29, 577-606.

  81. Gillespie PG, Gillespie SKH, Mercer JA, Shah K, Shokat KM.(1999) Engineering of the myosin-Ib nucleotide-binding pocket to create sensitivity to N6-modified ADP analogsJ. Biol. Chem. 274(44), 31373-31381.

  82. Bishop AC, Kung C-Y, Shah K, Witucki L, Shokat KM, Liu Y. (1999) Generation of monospecific nanomol ar tyrosine kinase inhibitors via a chemical genetic approachJ. Am. Chem. Soc. 121(4), 627-631.

  83. Liu Y, Shah K, Yang F, Witucki L, Shokat KM. (1998)A Molecular Gate Which Controls Unnatural ATP Analog Recognition by the Tyrosine Kinase  v-Src Bioorganic & Medicinal Chemistry 6(8), 1219-

  84. Liu Y, Shah K, Yang F, Witucki L, Shokat KM. (1997) Engineering Src Family Protein Kinases with Unnatural Nucleotide SpecificityChemistry & Biology 5(2), 91-102.

  85. Bishop AC, Shah K, Liu Y, Witucki L, Kung C-Y, Shokat KM. (1997) Design of allele specific inhibitors to probe protein kinase signalingCurrent Biology 8, 257-266.

  86. Shah K, Liu Y, Diermengian C, & Shokat KM. (1997) Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substratesProc. Natl. Acad.Sci. USA 94, 3565-3570.

  87. Shah K, Neenhold H, Wang Z, Rana TM. (1996) Incorporation of an artificial protease and nuclease at the HIV-1 Tat binding site of trans-activation responsive RNA. Bioconjug Chem, 7(3), 283-9.

  88. Shah K, Rana TM. (1996) Synthesis of N-a-Fmoc-N-e-tetrabutyl ester-EDTA-l- Lysine: An amino acid analog to prepare Affinity Cleaving Peptides.Synthetic Communications, 26(14), 2695-2702.

  89. Shah K, Wu H, Rana TM. (1994) Synthesis of uridine phosphoramidite analogs: reagents for site-specific incorporation of photoreactive sites into RNA sequencesBioconjug Chem 5(6), 508-12.

  90. Karle IL, Ranganathan D, Shah K, Vaish NK. (1994) Conformation of the oxalamide group in retro-bispeptides. Three crystal structures. Int J Pept Protein Res. 43(2), 160-5.

  91. Ranganathan D, Vaish NK, Shah K. (1994) Protein Backbone Modification by Novel Ca-C Side Chain Scission.J. Am. Chem. Soc., 116, 6545-6557.

  92. Ranganathan D, Vaish NK, Shah K, Roy R, Madhusudanan KP. (1993) Oxalopeptides as Core Motifs for Protein Design. J. Chem. Soc., Chem. Commun., 92-94.

  93. Ranganathan D, Shah K, Vaish NK. (1992) An Exceptionally Mild and Efficient Route to Dehydroalanine Peptides.J. Chem. Soc. Chem. Commun., 1145-1147.

  94. Bhattacharya I, Shah K, Vankar PS, Vankar YD. (1993) A convenient synthesis of vinyl epoxides from glycidic esters via a-hydroxy-b,g-unsaturated esters. Synth. Commun. 23, 2405.

  95. Vankar YD, Shah K. (1991)Facile conversion of tetrahydropyranylated alcohols to the corresponding bromides and iodides using metal halides and chlorotrimethylsilane (or boron trifluoride etherate). Tetrahedron Lett. 32, 1081.

  96. Vankar YD, Shah K, Bawa A, Singh SP. (1991) Preparation of α-nitroepoxides: Preparation of useful intermediates via nucleophilic ring opening of α-nitroepoxides. Tetrahedron 47, 8883.